CVS Health Corp vs HCA Health Inc — how do they compare? CVS Health Corp trades at $86.16 (market cap $112.29B), while HCA Health Inc trades at $451.09 (market cap $96.35B). The key difference: CVS Health Corp is the larger of the two by market cap, and CVS Health Corp pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and HCA Health Inc for 76 Days on average.
| CVS | HCA | |
|---|---|---|
Market Cap | $112.29B | $96.35B |
Volume | 7,763,676 | 1,079,453 |
Sector | Health | Health |
52-Week High | $110.60 | $545.13 |
52-Week Low | $70.08 | $361.32 |
Typical Hold Time | 83 Days | 76 Days |
Enterprise Value | $174.64B | $146.88B |
Dividend Yield | 3.03% | 0.7% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $86.16, down 2.04% for the day, amid a bearish technical signal. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.58 exceeding the $1.85 estimate. Revenue grew to $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst consensus is overwhelmingly positive, with 35 of 41 analysts rating the stock a Buy and a consensus price target of $111.20, implying significant upside. Recent news highlights Aetna's 2027 Medicare plan updates and a quarterly dividend declaration.
The outlook for CVS remains favorable based on fundamental strength and analyst optimism, but risks include reimbursement pressure, regulatory scrutiny, and a high debt load. The stock's current valuation metrics, such as a P/E of 23.17 and P/S of 0.27, appear reasonable relative to historical levels, supporting a constructive view for long-term investors despite near-term technical weakness.
HCA Healthcare trades at $451.09, up 2.71% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q4 2025 and Q1-Q2 2026 exceeding expectations, supported by robust revenue growth from $70.6B in 2024 to $75.6B in 2025. Valuation metrics remain attractive with P/E of 14.92 and P/S of 1.31, while technical indicators signal bullish momentum above key support levels.
The outlook remains positive with 63% analyst buy ratings and $461.12 consensus target, though legal investigations and high debt levels pose risks. Revenue growth and operational efficiency provide upside potential, but investors should monitor regulatory developments and debt management closely given the 80.9% debt-to-asset ratio in 2025.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →